ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com



Ò½ÏßÒ©ÎÅ1. 2ÔÂ11ÈÕ£¬£¬£¬£¬ÖйúÉúÎï¹Ù΢ÐÂÎÅ£¬£¬£¬£¬¿ËÈÕ£¬£¬£¬£¬¹úÒ©¼¯ÍÅÖйúÉúÎï±±¾©ÉúÎïÖÆÆ·Ñо¿ËùÑз¢µÄÕý¶»²¡¶¾Ñ¬È¾ÖÎÁÆÒ©Îï¡°×¢ÉäÓÃBSY1¡±ÒÑ»ñ¹ú¼ÒÒ©¼à¾ÖÁÙ´²ÊÔÑéÅú×¼¡£¡£¡£¡£¡£¡£ÕâÊÇÎÒ¹úÊ׿î»ñÅúÁÙ´²µÄ¹ãÆ×¿¹Õý¶»²¡¶¾ÖÎÁÆÒ©Î£¬£¬£¬Õë¶ÔÌ컨¡¢ºï¶»µÈÕý¶»²¡¶¾¡£¡£¡£¡£¡£¡£
2. 2ÔÂ12ÈÕ£¬£¬£¬£¬¾ÝCDE¹ÙÍø£¬£¬£¬£¬ËÕÖÝÐÅŵάҽҩ¿Æ¼¼¹É·ÝÓÐÏÞ¹«Ë¾ÁªºÏÉêÇëÒ©Æ·¡°XNW5004Ƭ¡±£¬£¬£¬£¬»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬Ë³Ó¦Ö¢£ºXNW5004ÁªºÏCHOP/CHOEPÄâÓÃÓÚÖÎÁƳõÖÎÍâÖÜTϸ°ûÁܰÍÁö¡£¡£¡£¡£¡£¡£
3. 2ÔÂ11ÈÕ£¬£¬£¬£¬NMPA¹ÙÍø¹«Ê¾£¬£¬£¬£¬ÓÉĬɳ¶«£¨MSD£©É걨µÄ5.1ÀàÐÂÒ©×¢ÉäÓÃÍ·æßÂåÉúËûßò°ÍÌ¹ÄÆÉÏÊÐÉêÇëÒÑ»ñµÃÅú×¼¡£¡£¡£¡£¡£¡£¿£¿£¿£¿£¿ª×ÊÁÏÏÔʾ£¬£¬£¬£¬ÕâÊÇÒ»¿î¸´·½¿¹¾úÒ©ÎÉÌÆ·ÃûΪZerbaxa£©£¬£¬£¬£¬°üÀ¨Í·æßÀ࿹ÉúËØÍ·æßÂåÉú£¨ceftolozane£©ºÍ¦Â-ÄÚõ£°·Ã¸ÒÖÖÆ¼ÁËûßò°Í̹£¨tazobactam£©¡£¡£¡£¡£¡£¡£
4. 2ÔÂ11ÈÕ£¬£¬£¬£¬¼Ã´¨Ò©ÒµÍ¨¸æ³Æ£¬£¬£¬£¬¹«Ë¾È«×Ê×Ó¹«Ë¾¼Ã´¨ÓÐÏÞÊÕµ½¹ú¼ÒÒ©¼à¾ÖÅú׼ǩ·¢µÄÎ÷ËûɳÐÇ¿ÅÁ£¡¶Ò©Æ·×¢²áÖ¤Êé¡·¡£¡£¡£¡£¡£¡£¸ÃҩƷΪº£ÄÚÊ×·ÂÉÏÊУ¬£¬£¬£¬ÊÊÓÃÓÚ¶ÔÎ÷ËûɳÐÇÃô¸ÐµÄ½ð»ÆÉ«ÆÏÌÑÇò¾úµÈËùÒýÆðµÄ¶àÖÖѬȾ¡£¡£¡£¡£¡£¡£
1. 2ÔÂ11ÈÕ£¬£¬£¬£¬ÀñÀ´Ðû²¼Ó뺫¹úÉúÎï¼¼Êõ¹«Ë¾OliX Pharmaceuticals¸æ¿¢Ò»Ïî¼ÛÖµ6.3ÒÚÃÀÔªµÄÈ«ÇòÔÊÐíÐÒ飬£¬£¬£¬ÅäºÏ¿ª·¢ºÍÉÌÒµ»¯OliXµÄ´úлÏà¹ØÖ¬·¾ÐÔ¸ÎÑ×£¨MASH£©ÖÎÁÆÒ©ÎïOLX75016¡£¡£¡£¡£¡£¡£
2. ÍâµØÊ±¼ä2ÔÂ11ÈÕ£¬£¬£¬£¬Åµ»ª¹«Ë¾Ðû²¼½«ÒÔ×î¸ß31ÒÚÃÀÔªµÄ¼ÛÇ®ÊÕ¹º×ܲ¿Î»ÓÚ²¨Ê¿¶ÙµÄ˽ÈËÁÙ´²½×¶ÎÉúÎïÖÆÒ©¹«Ë¾Anthos Therapeutics¡£¡£¡£¡£¡£¡£´Ë´ÎÊÕ¹ºÔÚÒ½Ò©ÐÐÒµÄÚÒýÆðÁËÆÕ±é¹Ø×¢£¬£¬£¬£¬²»µ«ÓÉÓÚÆäÉúÒâ½ð¶îÖØ´ó£¬£¬£¬£¬¸üÒòÆä±³ºóËù·´Ó¦³öµÄŵ»ªÔÚÐÄѪ¹ÜÁìÓòµÄÕ½ÂԽṹºÍÐÐÒµÉú³¤Ç÷ÊÆ¡£¡£¡£¡£¡£¡£Æ¾Ö¤ÉúÒâÌõ¿î£¬£¬£¬£¬Åµ»ª½«ÔÚÉúÒâÍê³ÉºóÖ§¸¶9.25ÒÚÃÀÔªµÄÔ¤¸¶¿î£¬£¬£¬£¬²¢ÔÚµÖ´ï»®¶¨µÄî¿ÏµºÍÏúÊÛÀï³Ì±®ºó£¬£¬£¬£¬¿ÉÄÜÌØÊâÖ§¸¶¸ß´ï21.5ÒÚÃÀÔª¡£¡£¡£¡£¡£¡£¸ÃÉúÒâÔ¤¼Æ½«ÓÚ2025ÄêÉϰëÄêÍê³É£¬£¬£¬£¬µ«ÐëÖª×ãÀÏÀý³É½»Ìõ¼þ¡£¡£¡£¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬£¬À´×ÔÒâ´óÀûµÄÑо¿ÍŶÓÔÚ Nature Medicine ÉϽÒÏþÁËÌâΪ Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma µÄÂÛÎÄ£¬£¬£¬£¬ÔÚNCT03373097 ×ÔÌåCAR-TÖÎÁÆÉñ¾Ä¸Ï¸°ûÁöµÄ»ù´¡ÉÏ£¬£¬£¬£¬Ì½Ë÷ÓÃͬÖÖÒìÌåGD2-CAR Tϸ°û£¨ALLO_GD2-CART01£©ÖÎÁÆr/r HR-NB¡£¡£¡£¡£¡£¡£ÔÚ5Àý»¼ÕßÖÐÊӲ쵽2ÀýÍêÈ«»º½â£¬£¬£¬£¬Ò»Àýά³Ö»º½â£¬£¬£¬£¬ÏÔʾ³öÆðÔ´Ï£Íû£¬£¬£¬£¬Ò²Òâζ×ÅALLO_GD2-CART01 ¶Ô r/r HR-NB ¶ùͯµÄÇå¾²ÐÔºÍÓÐÓÃÐÔÖµµÃÔÚǰհÐÔÊÔÑéÖнøÒ»²½Ñо¿¡£¡£¡£¡£¡£¡£
[1]Quintarelli, C., Del Bufalo, F., De Ioris, M.A. et al. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Nat Med (2025). https://doi.org/10.1038/s41591-024-03449-x